The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Varicella Attenuated Live Vaccination Market Research Report 2025
Synopsis
A live attenuated varicella vaccine, derived from the Oka strain of VZV has clinical efficacy for the prevention of varicella.
The global Varicella Attenuated Live Vaccination market was valued at US$ 2553.6 million in 2023 and is anticipated to reach US$ 3132.5 million by 2030, witnessing a CAGR of 2.9% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Varicella Attenuated Live Vaccination, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Varicella Attenuated Live Vaccination.
Report Scope
The Varicella Attenuated Live Vaccination market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Varicella Attenuated Live Vaccination market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Varicella Attenuated Live Vaccination manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck
BCHT
Shanghai Institute
GSK
Keygen
Green Cross
Biken
Shanghai Rongsheng Biotech
Changsheng
Segment by Type
Monovalent Vaccine
Combination Vaccine
Segment by Application
Children
Adults
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Varicella Attenuated Live Vaccination manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Varicella Attenuated Live Vaccination in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
A live attenuated varicella vaccine, derived from the Oka strain of VZV has clinical efficacy for the prevention of varicella.
The global Varicella Attenuated Live Vaccination market was valued at US$ 2553.6 million in 2023 and is anticipated to reach US$ 3132.5 million by 2030, witnessing a CAGR of 2.9% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Varicella Attenuated Live Vaccination, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Varicella Attenuated Live Vaccination.
Report Scope
The Varicella Attenuated Live Vaccination market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Varicella Attenuated Live Vaccination market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Varicella Attenuated Live Vaccination manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck
BCHT
Shanghai Institute
GSK
Keygen
Green Cross
Biken
Shanghai Rongsheng Biotech
Changsheng
Segment by Type
Monovalent Vaccine
Combination Vaccine
Segment by Application
Children
Adults
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Varicella Attenuated Live Vaccination manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Varicella Attenuated Live Vaccination in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Varicella Attenuated Live Vaccination Market Overview
1.1 Product Overview and Scope of Varicella Attenuated Live Vaccination
1.2 Varicella Attenuated Live Vaccination Segment by Type
1.2.1 Global Varicella Attenuated Live Vaccination Market Value Comparison by Type (2024-2030)
1.2.2 Monovalent Vaccine
1.2.3 Combination Vaccine
1.3 Varicella Attenuated Live Vaccination Segment by Application
1.3.1 Global Varicella Attenuated Live Vaccination Market Value by Application: (2024-2030)
1.3.2 Children
1.3.3 Adults
1.4 Global Varicella Attenuated Live Vaccination Market Size Estimates and Forecasts
1.4.1 Global Varicella Attenuated Live Vaccination Revenue 2019-2030
1.4.2 Global Varicella Attenuated Live Vaccination Sales 2019-2030
1.4.3 Global Varicella Attenuated Live Vaccination Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Varicella Attenuated Live Vaccination Market Competition by Manufacturers
2.1 Global Varicella Attenuated Live Vaccination Sales Market Share by Manufacturers (2019-2024)
2.2 Global Varicella Attenuated Live Vaccination Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Varicella Attenuated Live Vaccination Average Price by Manufacturers (2019-2024)
2.4 Global Varicella Attenuated Live Vaccination Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Varicella Attenuated Live Vaccination, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Varicella Attenuated Live Vaccination, Product Type & Application
2.7 Varicella Attenuated Live Vaccination Market Competitive Situation and Trends
2.7.1 Varicella Attenuated Live Vaccination Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Varicella Attenuated Live Vaccination Players Market Share by Revenue
2.7.3 Global Varicella Attenuated Live Vaccination Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Varicella Attenuated Live Vaccination Retrospective Market Scenario by Region
3.1 Global Varicella Attenuated Live Vaccination Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Varicella Attenuated Live Vaccination Global Varicella Attenuated Live Vaccination Sales by Region: 2019-2030
3.2.1 Global Varicella Attenuated Live Vaccination Sales by Region: 2019-2024
3.2.2 Global Varicella Attenuated Live Vaccination Sales by Region: 2025-2030
3.3 Global Varicella Attenuated Live Vaccination Global Varicella Attenuated Live Vaccination Revenue by Region: 2019-2030
3.3.1 Global Varicella Attenuated Live Vaccination Revenue by Region: 2019-2024
3.3.2 Global Varicella Attenuated Live Vaccination Revenue by Region: 2025-2030
3.4 North America Varicella Attenuated Live Vaccination Market Facts & Figures by Country
3.4.1 North America Varicella Attenuated Live Vaccination Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Varicella Attenuated Live Vaccination Sales by Country (2019-2030)
3.4.3 North America Varicella Attenuated Live Vaccination Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Varicella Attenuated Live Vaccination Market Facts & Figures by Country
3.5.1 Europe Varicella Attenuated Live Vaccination Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Varicella Attenuated Live Vaccination Sales by Country (2019-2030)
3.5.3 Europe Varicella Attenuated Live Vaccination Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Varicella Attenuated Live Vaccination Market Facts & Figures by Country
3.6.1 Asia Pacific Varicella Attenuated Live Vaccination Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Varicella Attenuated Live Vaccination Sales by Country (2019-2030)
3.6.3 Asia Pacific Varicella Attenuated Live Vaccination Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Varicella Attenuated Live Vaccination Market Facts & Figures by Country
3.7.1 Latin America Varicella Attenuated Live Vaccination Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Varicella Attenuated Live Vaccination Sales by Country (2019-2030)
3.7.3 Latin America Varicella Attenuated Live Vaccination Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Varicella Attenuated Live Vaccination Market Facts & Figures by Country
3.8.1 Middle East and Africa Varicella Attenuated Live Vaccination Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Varicella Attenuated Live Vaccination Sales by Country (2019-2030)
3.8.3 Middle East and Africa Varicella Attenuated Live Vaccination Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Varicella Attenuated Live Vaccination Sales by Type (2019-2030)
4.1.1 Global Varicella Attenuated Live Vaccination Sales by Type (2019-2024)
4.1.2 Global Varicella Attenuated Live Vaccination Sales by Type (2025-2030)
4.1.3 Global Varicella Attenuated Live Vaccination Sales Market Share by Type (2019-2030)
4.2 Global Varicella Attenuated Live Vaccination Revenue by Type (2019-2030)
4.2.1 Global Varicella Attenuated Live Vaccination Revenue by Type (2019-2024)
4.2.2 Global Varicella Attenuated Live Vaccination Revenue by Type (2025-2030)
4.2.3 Global Varicella Attenuated Live Vaccination Revenue Market Share by Type (2019-2030)
4.3 Global Varicella Attenuated Live Vaccination Price by Type (2019-2030)
5 Segment by Application
5.1 Global Varicella Attenuated Live Vaccination Sales by Application (2019-2030)
5.1.1 Global Varicella Attenuated Live Vaccination Sales by Application (2019-2024)
5.1.2 Global Varicella Attenuated Live Vaccination Sales by Application (2025-2030)
5.1.3 Global Varicella Attenuated Live Vaccination Sales Market Share by Application (2019-2030)
5.2 Global Varicella Attenuated Live Vaccination Revenue by Application (2019-2030)
5.2.1 Global Varicella Attenuated Live Vaccination Revenue by Application (2019-2024)
5.2.2 Global Varicella Attenuated Live Vaccination Revenue by Application (2025-2030)
5.2.3 Global Varicella Attenuated Live Vaccination Revenue Market Share by Application (2019-2030)
5.3 Global Varicella Attenuated Live Vaccination Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Merck
6.1.1 Merck Corporation Information
6.1.2 Merck Description and Business Overview
6.1.3 Merck Varicella Attenuated Live Vaccination Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Merck Varicella Attenuated Live Vaccination Product Portfolio
6.1.5 Merck Recent Developments/Updates
6.2 BCHT
6.2.1 BCHT Corporation Information
6.2.2 BCHT Description and Business Overview
6.2.3 BCHT Varicella Attenuated Live Vaccination Sales, Revenue and Gross Margin (2019-2024)
6.2.4 BCHT Varicella Attenuated Live Vaccination Product Portfolio
6.2.5 BCHT Recent Developments/Updates
6.3 Shanghai Institute
6.3.1 Shanghai Institute Corporation Information
6.3.2 Shanghai Institute Description and Business Overview
6.3.3 Shanghai Institute Varicella Attenuated Live Vaccination Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Shanghai Institute Varicella Attenuated Live Vaccination Product Portfolio
6.3.5 Shanghai Institute Recent Developments/Updates
6.4 GSK
6.4.1 GSK Corporation Information
6.4.2 GSK Description and Business Overview
6.4.3 GSK Varicella Attenuated Live Vaccination Sales, Revenue and Gross Margin (2019-2024)
6.4.4 GSK Varicella Attenuated Live Vaccination Product Portfolio
6.4.5 GSK Recent Developments/Updates
6.5 Keygen
6.5.1 Keygen Corporation Information
6.5.2 Keygen Description and Business Overview
6.5.3 Keygen Varicella Attenuated Live Vaccination Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Keygen Varicella Attenuated Live Vaccination Product Portfolio
6.5.5 Keygen Recent Developments/Updates
6.6 Green Cross
6.6.1 Green Cross Corporation Information
6.6.2 Green Cross Description and Business Overview
6.6.3 Green Cross Varicella Attenuated Live Vaccination Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Green Cross Varicella Attenuated Live Vaccination Product Portfolio
6.6.5 Green Cross Recent Developments/Updates
6.7 Biken
6.6.1 Biken Corporation Information
6.6.2 Biken Description and Business Overview
6.6.3 Biken Varicella Attenuated Live Vaccination Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Biken Varicella Attenuated Live Vaccination Product Portfolio
6.7.5 Biken Recent Developments/Updates
6.8 Shanghai Rongsheng Biotech
6.8.1 Shanghai Rongsheng Biotech Corporation Information
6.8.2 Shanghai Rongsheng Biotech Description and Business Overview
6.8.3 Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccination Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccination Product Portfolio
6.8.5 Shanghai Rongsheng Biotech Recent Developments/Updates
6.9 Changsheng
6.9.1 Changsheng Corporation Information
6.9.2 Changsheng Description and Business Overview
6.9.3 Changsheng Varicella Attenuated Live Vaccination Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Changsheng Varicella Attenuated Live Vaccination Product Portfolio
6.9.5 Changsheng Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Varicella Attenuated Live Vaccination Industry Chain Analysis
7.2 Varicella Attenuated Live Vaccination Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Varicella Attenuated Live Vaccination Production Mode & Process
7.4 Varicella Attenuated Live Vaccination Sales and Marketing
7.4.1 Varicella Attenuated Live Vaccination Sales Channels
7.4.2 Varicella Attenuated Live Vaccination Distributors
7.5 Varicella Attenuated Live Vaccination Customers
8 Varicella Attenuated Live Vaccination Market Dynamics
8.1 Varicella Attenuated Live Vaccination Industry Trends
8.2 Varicella Attenuated Live Vaccination Market Drivers
8.3 Varicella Attenuated Live Vaccination Market Challenges
8.4 Varicella Attenuated Live Vaccination Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Varicella Attenuated Live Vaccination Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Varicella Attenuated Live Vaccination Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Varicella Attenuated Live Vaccination Market Competitive Situation by Manufacturers in 2023
Table 4. Global Varicella Attenuated Live Vaccination Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Varicella Attenuated Live Vaccination Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Varicella Attenuated Live Vaccination Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Varicella Attenuated Live Vaccination Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Varicella Attenuated Live Vaccination Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Varicella Attenuated Live Vaccination, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Varicella Attenuated Live Vaccination, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Varicella Attenuated Live Vaccination, Product Type & Application
Table 12. Global Key Manufacturers of Varicella Attenuated Live Vaccination, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Varicella Attenuated Live Vaccination by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Varicella Attenuated Live Vaccination as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Varicella Attenuated Live Vaccination Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Varicella Attenuated Live Vaccination Sales by Region (2019-2024) & (K Units)
Table 18. Global Varicella Attenuated Live Vaccination Sales Market Share by Region (2019-2024)
Table 19. Global Varicella Attenuated Live Vaccination Sales by Region (2025-2030) & (K Units)
Table 20. Global Varicella Attenuated Live Vaccination Sales Market Share by Region (2025-2030)
Table 21. Global Varicella Attenuated Live Vaccination Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Varicella Attenuated Live Vaccination Revenue Market Share by Region (2019-2024)
Table 23. Global Varicella Attenuated Live Vaccination Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Varicella Attenuated Live Vaccination Revenue Market Share by Region (2025-2030)
Table 25. North America Varicella Attenuated Live Vaccination Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Varicella Attenuated Live Vaccination Sales by Country (2019-2024) & (K Units)
Table 27. North America Varicella Attenuated Live Vaccination Sales by Country (2025-2030) & (K Units)
Table 28. North America Varicella Attenuated Live Vaccination Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Varicella Attenuated Live Vaccination Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Varicella Attenuated Live Vaccination Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Varicella Attenuated Live Vaccination Sales by Country (2019-2024) & (K Units)
Table 32. Europe Varicella Attenuated Live Vaccination Sales by Country (2025-2030) & (K Units)
Table 33. Europe Varicella Attenuated Live Vaccination Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Varicella Attenuated Live Vaccination Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Varicella Attenuated Live Vaccination Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Varicella Attenuated Live Vaccination Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Varicella Attenuated Live Vaccination Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Varicella Attenuated Live Vaccination Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Varicella Attenuated Live Vaccination Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Varicella Attenuated Live Vaccination Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Varicella Attenuated Live Vaccination Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Varicella Attenuated Live Vaccination Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Varicella Attenuated Live Vaccination Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Varicella Attenuated Live Vaccination Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Varicella Attenuated Live Vaccination Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Varicella Attenuated Live Vaccination Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Varicella Attenuated Live Vaccination Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Varicella Attenuated Live Vaccination Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Varicella Attenuated Live Vaccination Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Varicella Attenuated Live Vaccination Sales (K Units) by Type (2019-2024)
Table 51. Global Varicella Attenuated Live Vaccination Sales (K Units) by Type (2025-2030)
Table 52. Global Varicella Attenuated Live Vaccination Sales Market Share by Type (2019-2024)
Table 53. Global Varicella Attenuated Live Vaccination Sales Market Share by Type (2025-2030)
Table 54. Global Varicella Attenuated Live Vaccination Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Varicella Attenuated Live Vaccination Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Varicella Attenuated Live Vaccination Revenue Market Share by Type (2019-2024)
Table 57. Global Varicella Attenuated Live Vaccination Revenue Market Share by Type (2025-2030)
Table 58. Global Varicella Attenuated Live Vaccination Price (US$/Unit) by Type (2019-2024)
Table 59. Global Varicella Attenuated Live Vaccination Price (US$/Unit) by Type (2025-2030)
Table 60. Global Varicella Attenuated Live Vaccination Sales (K Units) by Application (2019-2024)
Table 61. Global Varicella Attenuated Live Vaccination Sales (K Units) by Application (2025-2030)
Table 62. Global Varicella Attenuated Live Vaccination Sales Market Share by Application (2019-2024)
Table 63. Global Varicella Attenuated Live Vaccination Sales Market Share by Application (2025-2030)
Table 64. Global Varicella Attenuated Live Vaccination Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Varicella Attenuated Live Vaccination Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Varicella Attenuated Live Vaccination Revenue Market Share by Application (2019-2024)
Table 67. Global Varicella Attenuated Live Vaccination Revenue Market Share by Application (2025-2030)
Table 68. Global Varicella Attenuated Live Vaccination Price (US$/Unit) by Application (2019-2024)
Table 69. Global Varicella Attenuated Live Vaccination Price (US$/Unit) by Application (2025-2030)
Table 70. Merck Corporation Information
Table 71. Merck Description and Business Overview
Table 72. Merck Varicella Attenuated Live Vaccination Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. Merck Varicella Attenuated Live Vaccination Product
Table 74. Merck Recent Developments/Updates
Table 75. BCHT Corporation Information
Table 76. BCHT Description and Business Overview
Table 77. BCHT Varicella Attenuated Live Vaccination Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. BCHT Varicella Attenuated Live Vaccination Product
Table 79. BCHT Recent Developments/Updates
Table 80. Shanghai Institute Corporation Information
Table 81. Shanghai Institute Description and Business Overview
Table 82. Shanghai Institute Varicella Attenuated Live Vaccination Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. Shanghai Institute Varicella Attenuated Live Vaccination Product
Table 84. Shanghai Institute Recent Developments/Updates
Table 85. GSK Corporation Information
Table 86. GSK Description and Business Overview
Table 87. GSK Varicella Attenuated Live Vaccination Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. GSK Varicella Attenuated Live Vaccination Product
Table 89. GSK Recent Developments/Updates
Table 90. Keygen Corporation Information
Table 91. Keygen Description and Business Overview
Table 92. Keygen Varicella Attenuated Live Vaccination Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Keygen Varicella Attenuated Live Vaccination Product
Table 94. Keygen Recent Developments/Updates
Table 95. Green Cross Corporation Information
Table 96. Green Cross Description and Business Overview
Table 97. Green Cross Varicella Attenuated Live Vaccination Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. Green Cross Varicella Attenuated Live Vaccination Product
Table 99. Green Cross Recent Developments/Updates
Table 100. Biken Corporation Information
Table 101. Biken Description and Business Overview
Table 102. Biken Varicella Attenuated Live Vaccination Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. Biken Varicella Attenuated Live Vaccination Product
Table 104. Biken Recent Developments/Updates
Table 105. Shanghai Rongsheng Biotech Corporation Information
Table 106. Shanghai Rongsheng Biotech Description and Business Overview
Table 107. Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccination Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccination Product
Table 109. Shanghai Rongsheng Biotech Recent Developments/Updates
Table 110. Changsheng Corporation Information
Table 111. Changsheng Description and Business Overview
Table 112. Changsheng Varicella Attenuated Live Vaccination Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 113. Changsheng Varicella Attenuated Live Vaccination Product
Table 114. Changsheng Recent Developments/Updates
Table 115. Key Raw Materials Lists
Table 116. Raw Materials Key Suppliers Lists
Table 117. Varicella Attenuated Live Vaccination Distributors List
Table 118. Varicella Attenuated Live Vaccination Customers List
Table 119. Varicella Attenuated Live Vaccination Market Trends
Table 120. Varicella Attenuated Live Vaccination Market Drivers
Table 121. Varicella Attenuated Live Vaccination Market Challenges
Table 122. Varicella Attenuated Live Vaccination Market Restraints
Table 123. Research Programs/Design for This Report
Table 124. Key Data Information from Secondary Sources
Table 125. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Varicella Attenuated Live Vaccination
Figure 2. Global Varicella Attenuated Live Vaccination Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Varicella Attenuated Live Vaccination Market Share by Type in 2023 & 2030
Figure 4. Monovalent Vaccine Product Picture
Figure 5. Combination Vaccine Product Picture
Figure 6. Global Varicella Attenuated Live Vaccination Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Varicella Attenuated Live Vaccination Market Share by Application in 2023 & 2030
Figure 8. Children
Figure 9. Adults
Figure 10. Global Varicella Attenuated Live Vaccination Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 11. Global Varicella Attenuated Live Vaccination Market Size (2019-2030) & (US$ Million)
Figure 12. Global Varicella Attenuated Live Vaccination Sales (2019-2030) & (K Units)
Figure 13. Global Varicella Attenuated Live Vaccination Average Price (US$/Unit) & (2019-2030)
Figure 14. Varicella Attenuated Live Vaccination Report Years Considered
Figure 15. Varicella Attenuated Live Vaccination Sales Share by Manufacturers in 2023
Figure 16. Global Varicella Attenuated Live Vaccination Revenue Share by Manufacturers in 2023
Figure 17. The Global 5 and 10 Largest Varicella Attenuated Live Vaccination Players: Market Share by Revenue in 2023
Figure 18. Varicella Attenuated Live Vaccination Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 19. Global Varicella Attenuated Live Vaccination Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 20. North America Varicella Attenuated Live Vaccination Sales Market Share by Country (2019-2030)
Figure 21. North America Varicella Attenuated Live Vaccination Revenue Market Share by Country (2019-2030)
Figure 22. United States Varicella Attenuated Live Vaccination Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 23. Canada Varicella Attenuated Live Vaccination Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 24. Europe Varicella Attenuated Live Vaccination Sales Market Share by Country (2019-2030)
Figure 25. Europe Varicella Attenuated Live Vaccination Revenue Market Share by Country (2019-2030)
Figure 26. Germany Varicella Attenuated Live Vaccination Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 27. France Varicella Attenuated Live Vaccination Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. U.K. Varicella Attenuated Live Vaccination Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. Italy Varicella Attenuated Live Vaccination Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. Russia Varicella Attenuated Live Vaccination Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Asia Pacific Varicella Attenuated Live Vaccination Sales Market Share by Region (2019-2030)
Figure 32. Asia Pacific Varicella Attenuated Live Vaccination Revenue Market Share by Region (2019-2030)
Figure 33. China Varicella Attenuated Live Vaccination Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. Japan Varicella Attenuated Live Vaccination Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. South Korea Varicella Attenuated Live Vaccination Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. India Varicella Attenuated Live Vaccination Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. Australia Varicella Attenuated Live Vaccination Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. China Taiwan Varicella Attenuated Live Vaccination Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Indonesia Varicella Attenuated Live Vaccination Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Thailand Varicella Attenuated Live Vaccination Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Malaysia Varicella Attenuated Live Vaccination Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Latin America Varicella Attenuated Live Vaccination Sales Market Share by Country (2019-2030)
Figure 43. Latin America Varicella Attenuated Live Vaccination Revenue Market Share by Country (2019-2030)
Figure 44. Mexico Varicella Attenuated Live Vaccination Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Brazil Varicella Attenuated Live Vaccination Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Argentina Varicella Attenuated Live Vaccination Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Middle East & Africa Varicella Attenuated Live Vaccination Sales Market Share by Country (2019-2030)
Figure 48. Middle East & Africa Varicella Attenuated Live Vaccination Revenue Market Share by Country (2019-2030)
Figure 49. Turkey Varicella Attenuated Live Vaccination Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. Saudi Arabia Varicella Attenuated Live Vaccination Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. UAE Varicella Attenuated Live Vaccination Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. Global Sales Market Share of Varicella Attenuated Live Vaccination by Type (2019-2030)
Figure 53. Global Revenue Market Share of Varicella Attenuated Live Vaccination by Type (2019-2030)
Figure 54. Global Varicella Attenuated Live Vaccination Price (US$/Unit) by Type (2019-2030)
Figure 55. Global Sales Market Share of Varicella Attenuated Live Vaccination by Application (2019-2030)
Figure 56. Global Revenue Market Share of Varicella Attenuated Live Vaccination by Application (2019-2030)
Figure 57. Global Varicella Attenuated Live Vaccination Price (US$/Unit) by Application (2019-2030)
Figure 58. Varicella Attenuated Live Vaccination Value Chain
Figure 59. Varicella Attenuated Live Vaccination Production Process
Figure 60. Channels of Distribution (Direct Vs Distribution)
Figure 61. Distributors Profiles
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
